Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Silence Therapeutics ADR Representing 3 Ord Shs SLN

Healthcare Biotechnology
Silence Therapeutics plc is a United Kingdom-based biotechnology company. The Company is developing medicines by harnessing the body's natural mechanism of RNA interference, or RNAi, to inhibit the expression of specific target genes. The Company's mRNAi GOLD (GalNAc Oligonucleotide Discovery) platform can be used to create siRNAs (short interfering RNAs) that precisely target and silence... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:SLN)

Silence Therapeutics Reports First Quarter 2024 Results and Highlights Pipeline Progress

Business Wire 2 days ago

Silence Therapeutics to Participate in Fireside Chat at H.C. Wainwright 2nd Annual BioConnect Investor Conference

Business Wire April 30, 2024

Silence Therapeutics Announces Retirement of Alistair Gray from Board of Directors

Business Wire April 29, 2024

Silence Therapeutics Announces JAMA Publication of Additional Phase 1 Data for Zerlasiran in Subjects with Elevated Lipoprotein(a)

Business Wire April 8, 2024

Silence Therapeutics Reports Full Year 2023 Financial Results and Recent Business Highlights

Business Wire March 13, 2024

Silence Therapeutics Announces Positive Topline 36-Week Data from Ongoing Phase 2 Study of Zerlasiran in Patients with High Lipoprotein(a)

Business Wire March 13, 2024

Silence Therapeutics to Report Fourth Quarter and Full Year 2023 Results on March 13, 2024

Business Wire February 28, 2024

Silence Therapeutics Achieves $10 Million Milestone Payment from AstraZeneca Collaboration Following the Initiation of Phase 1 Trial

Business Wire February 23, 2024

Silence Therapeutics Announces Oversubscribed $120 Million Private Placement

Business Wire February 5, 2024
View More News ››

Opinion & Analysis (NDAQ:SLN)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:SLN)

Be the first to post on this bullboard.

Saturn Oil & Gas Inc.

Saturn Oil & Gas Inc.

Saturn Oil & Gas Inc. is a Canada-based energy company. The Company’s focus is to advance the exploration and development of ...
View More »